NASDAQ:DRMA Dermata Therapeutics - DRMA Stock Forecast, Price & News Notice: Trading of Dermata Therapeutics halted at 02:51 PM EST due to "LULD pause". Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.68 +0.34 (+25.37%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.26▼$1.9850-Day Range$1.34▼$51.5252-Week Range$1.26▼$23.52Volume1.65 million shsAverage Volume239,824 shsMarket Capitalization$1.29 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Dermata Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside138.1% Upside$4.00 Price TargetShort InterestHealthy2.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 stars 3.5 Analyst's Opinion Consensus RatingDermata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Dermata Therapeutics has a forecasted upside of 138.1% from its current price of $1.68.Amount of Analyst CoverageDermata Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.37% of the float of Dermata Therapeutics has been sold short.Short Interest Ratio / Days to CoverDermata Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dermata Therapeutics has recently decreased by 0.21%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDermata Therapeutics does not currently pay a dividend.Dividend GrowthDermata Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DRMA. Previous Next 3.2 News and Social Media Coverage News SentimentDermata Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Dermata Therapeutics this week, compared to 0 articles on an average week.Search Interest13 people have searched for DRMA on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders36.30% of the stock of Dermata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.63% of the stock of Dermata Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Dermata Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dermata Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDermata Therapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Dermata Therapeutics (NASDAQ:DRMA) StockDermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.Read More Receive DRMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DRMA Stock News HeadlinesMarch 20, 2023 | finance.yahoo.comDermata Therapeutics Announces Closing of $5.0 Million Public OfferingMarch 20, 2023 | finance.yahoo.comDermata Therapeutics Announces Closing of $5.0 Million Public OfferingMarch 23, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 16, 2023 | marketwatch.comDermata Therapeutics Up 24% After Boosting Size of OfferingMarch 16, 2023 | finance.yahoo.comDermata Therapeutics Announces Pricing of $5.0 Million Public OfferingFebruary 28, 2023 | seekingalpha.comDRMA Dermata Therapeutics, Inc.February 21, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial ResultsDecember 30, 2022 | benzinga.comThinking about buying stock in Dermata Therapeutics, Silo Pharma, IQIYI, First Wave BioPharma, or I-Mab?March 23, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!December 30, 2022 | benzinga.comWhy Dermata Therapeutics Stock Is Trading 100% Higher TodayDecember 30, 2022 | benzinga.comWhy Dermata Therapeutics Shares Are Trading Higher By Over 100%; Here Are 21 Stocks Moving PremarketNovember 10, 2022 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsSeptember 7, 2022 | finanznachrichten.deDermata Therapeutics: Dermata to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 6, 2022 | finance.yahoo.comDermata to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 25, 2022 | finanznachrichten.deDermata Therapeutics: Dermata to Participate in the Gilmartin Group Emerging Growth Company ShowcaseAugust 24, 2022 | finance.yahoo.comDermata to Participate in the Gilmartin Group Emerging Growth Company ShowcaseAugust 16, 2022 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsJune 13, 2022 | finance.yahoo.comDermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe RosaceaMay 23, 2022 | finanznachrichten.deDermata Therapeutics: Dermata to Present at the H.C. Wainwright Global Investment ConferenceMay 23, 2022 | finance.yahoo.comDermata to Present at the H.C. Wainwright Global Investment ConferenceMay 16, 2022 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ResultsApril 25, 2022 | finance.yahoo.comDermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesApril 21, 2022 | seekingalpha.comDermata Therapeutics launches $5M securities offeringApril 21, 2022 | finance.yahoo.comDermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesMarch 28, 2022 | seekingalpha.comDermata Therapeutics GAAP EPS of -$2.43 beats by $0.75March 28, 2022 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial ResultsMarch 24, 2022 | finance.yahoo.comDermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DRMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DRMA Company Calendar Last Earnings2/21/2023Today3/23/2023Next Earnings (Estimated)5/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRMA CUSIPN/A CIK1853816 Webwww.dermatarx.com Phone858-800-2543FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+1,067.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($14.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-124.00% Return on Assets-106.83% Debt Debt-to-Equity RatioN/A Current Ratio7.52 Quick Ratio7.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.82 per share Price / Book0.18Miscellaneous Outstanding Shares770,000Free Float490,000Market Cap$1.05 million OptionableNot Optionable Beta0.61 Key ExecutivesMr. Gerald T. Proehl (Age 63)Founder, Pres, CEO & Chairman Comp: $135.91kMr. David F. Hale (Age 73)Co-Founder & Lead Independent Director Comp: $27.19kMs. Kyri K. Van Hoose CPA (Age 43)M.B.A., Sr. VP & CFO Comp: $265.05kDr. Christopher J. Nardo M.P.H. (Age 57)Ph.D., Sr. VP & Chief Devel. Officer Comp: $356.4kMr. Sean ProehlSr. Director of Legal & Bus. Devel.Dr. Maria Bedoya Toro Munera M.B.A. (Age 70)Ph.D., Sr. VP of Regulatory Affairs & Quality Assurance More ExecutivesKey CompetitorsStatera BiopharmaNASDAQ:STABChina SXT PharmaceuticalsNASDAQ:SXTCTenax TherapeuticsNASDAQ:TENXJaguar HealthNASDAQ:JAGXSciSparcNASDAQ:SPRCView All CompetitorsInstitutional OwnershipRaymond James Financial Services Advisors Inc.Bought 141,763 shares on 2/8/2023Ownership: 1.151%View All Institutional Transactions DRMA Stock - Frequently Asked Questions Should I buy or sell Dermata Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dermata Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DRMA shares. View DRMA analyst ratings or view top-rated stocks. What is Dermata Therapeutics' stock price forecast for 2023? 2 equities research analysts have issued twelve-month price targets for Dermata Therapeutics' shares. Their DRMA share price forecasts range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 192.0% from the stock's current price. View analysts price targets for DRMA or view top-rated stocks among Wall Street analysts. How have DRMA shares performed in 2023? Dermata Therapeutics' stock was trading at $6.5440 at the beginning of 2023. Since then, DRMA stock has decreased by 79.1% and is now trading at $1.37. View the best growth stocks for 2023 here. When is Dermata Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023. View our DRMA earnings forecast. How were Dermata Therapeutics' earnings last quarter? Dermata Therapeutics, Inc. (NASDAQ:DRMA) released its earnings results on Tuesday, February, 21st. The company reported ($1.92) earnings per share for the quarter. When did Dermata Therapeutics' stock split? Dermata Therapeutics's stock reverse split on Tuesday, March 14th 2023. The 1-16 reverse split was announced on Tuesday, March 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Dermata Therapeutics IPO? (DRMA) raised $18 million in an initial public offering on Friday, August 13th 2021. The company issued 2,571,428 shares at $7.00 per share. What is Dermata Therapeutics' stock symbol? Dermata Therapeutics trades on the NASDAQ under the ticker symbol "DRMA." Who are Dermata Therapeutics' major shareholders? Dermata Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Raymond James Financial Services Advisors Inc. (1.15%). How do I buy shares of Dermata Therapeutics? Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Dermata Therapeutics' stock price today? One share of DRMA stock can currently be purchased for approximately $1.37. How much money does Dermata Therapeutics make? Dermata Therapeutics (NASDAQ:DRMA) has a market capitalization of $1.05 million. The company earns $-9,610,000.00 in net income (profit) each year or ($14.24) on an earnings per share basis. How can I contact Dermata Therapeutics? The official website for the company is www.dermatarx.com. The company can be reached via phone at 858-800-2543 or via email at sproehl@dermatarx.com. This page (NASDAQ:DRMA) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.